Humacyte, Inc.
HUMA
$0.58
-$0.02-2.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.12M | 2.02M | 2.04M | 1.57M | 818.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.12M | 2.02M | 2.04M | 1.57M | 818.00K |
| Cost of Revenue | 81.50M | 83.74M | 79.00M | 75.97M | 81.37M |
| Gross Profit | -79.37M | -81.72M | -76.97M | -74.40M | -80.55M |
| SG&A Expenses | 31.08M | 30.77M | 31.17M | 30.99M | 30.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.58M | 114.50M | 110.18M | 106.96M | 112.05M |
| Operating Income | -110.46M | -112.49M | -108.14M | -105.39M | -111.23M |
| Income Before Tax | -96.74M | -97.59M | -40.83M | -36.97M | -58.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.74 | -97.59 | -40.83 | -36.97 | -58.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.74M | -97.59M | -40.83M | -36.97M | -58.66M |
| EBIT | -110.46M | -112.49M | -108.14M | -105.39M | -111.23M |
| EBITDA | -103.23M | -105.19M | -100.79M | -98.02M | -103.92M |
| EPS Basic | -0.49 | -0.57 | -0.19 | -0.22 | -0.44 |
| Normalized Basic EPS | -0.29 | -0.33 | -0.31 | -0.40 | -0.47 |
| EPS Diluted | -0.49 | -0.58 | -0.19 | -0.22 | -0.44 |
| Normalized Diluted EPS | -0.29 | -0.33 | -0.31 | -0.40 | -0.47 |
| Average Basic Shares Outstanding | 777.13M | 698.38M | 632.16M | 572.36M | 533.46M |
| Average Diluted Shares Outstanding | 777.13M | 698.38M | 632.43M | 572.63M | 533.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |